Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nuvalent, Inc.NASDAQ: NUVL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $109.28M (cash outflow) rose 29.2% year over year, behind the +49.6% change in trailing-twelve-month net income. Sequentially, it fell 7.9% from the prior quarter. Over 3 fiscal years it compounded at +73.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$451M (+6.0%) for the fiscal year ending Dec 2026, a slowdown from the +63.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$109.28M-7.9% QoQ
- Last fiscal yearDec 2025
- -$425.38M+63.1% YoY
- LTMMar 2026
- -$450.07M+49.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +29.2% | +11.5% | -17.7 pp |
| 1 year | +63.1% | +6.0% | -57.1 pp |
| 3-year CAGR | +73.2% | -34.0% | -107.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (425.38M) USD
- Year-over-year change
- -63.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (425.38M) | -63.1% |
| FY2024 | 2024-12-31 | (260.76M) | -106.6% |
| FY2023 | 2023-12-31 | (126.22M) | -54.2% |
| FY2022 | 2022-12-31 | (81.85M) | -76.6% |
| FY2021 | 2021-12-31 | (46.34M) | — |
Net Income vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +49.6% is the 4th highest of 9, against a peer median of +24.1%.
- Over three fiscal years its annual growth of +73.2% compares with a peer median of +21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.38B USD | +152.9% | +50.8% | — | |
| LTM Sep 2026 | $901.05M USD | +144.5% | +16.7% | 19.1% | |
| LTM Jun 2026 | $894M USD | +47.4% | +26.4% | 1259.9% | |
| LTM Sep 2026 | $717.13M USD | -2481.4% | +50.8% | 159.1% | |
| LTM Sep 2026 | $456.14M USD | -6.6% | -3.6% | 1812.1% | |
| LTM Mar 2026 | $450.07M USD | +49.6% | +73.2% | — | |
| FY2025 | €322.84M EUR | +83.2% | +74.5% | — | |
| LTM Sep 2026 | $193.81M USD | +0.8% | +2.8% | 69.0% | |
| LTM Jun 2026 | $191.64M USD | -22.4% | -0.7% | 24.7% | |
| Peer median (excluding NUVL) | — | +24.1% | +21.5% | 114.1% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Depreciation & Amortization | 215K | (373K) | 0 | 0 | 0 |
| Deferred Income Tax | (215K) | (5.74M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.55M | 10.33M | 25.56M | 60.58M | 86.5M |
| Change in Working Capital | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.64M | 4.21M | 2.17M | (4.05M) | 24.6M |
| Other Working Capital | 300K | 2.72M | 8.86M | 15.89M | (5.39M) |
| Other Non-Cash Items | 846K | 5.74M | (10.11M) | 3.27M | 44.46M |
| Operating Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.04M) | (212.92M) | (459.49M) | (1.02B) | (1.06B) |
| Sales of Investments | 1.02M | 202.25M | 315.96M | 451.45M | 933.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (220.03M) | (10.67M) | (143.53M) | (573.51M) | (124.08M) |
| Debt Repayment | 284K | 0 | 0 | 0 | 0 |
| Common Stock Issued | 177.27M | 248.63M | 324.3M | 569.99M | 515.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.98M) | 286K | 12.55M | (1.11M) | 0 |
| Financing Cash Flow | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 58.19M | 173.28M | 93.58M | (189.7M) | 116.05M |
| Free Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.